CareDx has exclusively partnered with Miromatrix Medical to accelerate research using bioengineered organs for human transplantation.
Under the partnership, an innovative testing solution will be developed by CareDx for use by Miromatrix in pre-clinical animal models.
CareDx will also exclusively offer donor-derived cell-free DNA (dd-cfDNA) testing services for human clinical trials to support the non-invasive evaluation of acute allograft rejection in Miromatrix’s pipeline of human bioengineered organs.
More than 100,000 people in the US are estimated to be in the need of an organ transplant, but it is anticipated that more than half of them only will receive it in the next five years.
CareDx CEO and president Reg Seeto said: “We are committed to being at the forefront of driving the next wave of innovation to address the organ supply shortage in transplantation through this collaboration with Miromatrix.
“We hope one day that bioengineered organs will become a reality for the thousands of patients waiting for a life-saving organ.”
CareDx is engaged in the discovery, development and commercialisation of healthcare solutions for transplant patients and caregivers. It also offers genomics-based information for transplant patients.
Miromatrix has developed an advanced perfusion technology platform for the bioengineering of human transplant organs. The platform is expected to help address the shortage in the availability of human organs, with an initial focus on livers and kidneys.
Miromatrix CEO Dr Jeff Ross said: “CareDx is at the leading edge of transplant innovation and has been instrumental in driving paradigm shifts in clinical practice through their non-invasive testing services which are widely used by leading organ transplant centres across the US.
“Our partnership with CareDx allows us to tap into their expertise in ways that may help us accelerate our momentum as we drive the next wave of innovation with bioengineered alternatives for use in human organ transplants.”
